News

Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along

Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along

Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along

The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry. That's

The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry. That's

The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry. That's

Dividend stocks can be worth investing in, even if they don't offer big yields. That's particularly the case when it comes to companies that regularly raise their payouts. Although your initial

With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling

With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling

With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling

Everyone's portfolio should include a couple of monster stocks. What do I mean by "monster"? I'm talking about companies that have a solid earnings track record and offer bright prospects down the

Everyone's portfolio should include a couple of monster stocks. What do I mean by "monster"? I'm talking about companies that have a solid earnings track record and offer bright prospects down the

Everyone's portfolio should include a couple of monster stocks. What do I mean by "monster"? I'm talking about companies that have a solid earnings track record and offer bright prospects down the

Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for

Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for

Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for

Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to

Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to

You don't have to settle for puny dividend income. Thousands of stocks offer dividends. Many of them, though, have dividend yields that don't amount to a hill of beans.

What if you could invest in

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof